Chemoprevention of Lung Cancer Is Proving Difficult and Frustrating, Requiring New Approaches
Open Access
- 21 June 2000
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 92 (12) , 959-960
- https://doi.org/10.1093/jnci/92.12.959
Abstract
The long-awaited results from EUROSCAN (i.e., the European Study on Chemoprevention With Vitamin A and N-Acetylcysteine), the randomized two-by-two factorial trial of vitamin A (retinyl palmitate) and N-acetylcysteine in patients with treated cancers of the lung or head and neck, show no benefit from either agent alone or from the combination. Among 2592 participants who received maximal tolerable doses for 2 years with a mean follow-up of 49 months, 916 experienced recurrence, second primary tumor, or death. The findings were analyzed exhaustively (1).Keywords
This publication has 0 references indexed in Scilit: